Skip to main content
. Author manuscript; available in PMC: 2016 May 31.
Published in final edited form as: Cancer Lett. 2015 Feb 23;360(2):302–309. doi: 10.1016/j.canlet.2015.02.036

Fig. 4.

Fig. 4

CD47 specific antibodies inhibit tumor growth in a heterotopic HCC model. (A) HepG2-luc2 cells were injected subcutaneously into the axilla of NSG mice and allowed to grow for 2 weeks. Intraperitoneal injections of IgG, B6H12 or CD47mAb400 were administered twice-weekly thereafter. (B) Representative bioluminescent images of mice at week 2 and week 8 are shown. (C) Mice treated with anti-CD47 antibodies had less tumor bioluminescence than those treated with IgG antibody, with CD47mAb400 having a greater effect than B6H12 (mixed-effects model; p < 0.04 IgG vs B6H12; p < 0.003 IgG vs CD47mAb400). (D) Direct tumor size measurements showed that tumor growth initially continued with all antibodies. After the third week tumor growth was inhibited with B6H12 antibody, and tumor size regressed with CD47mAb400 antibody (mixed-effects model; p < 1e-5 for both IgG vs B6H12 and IgG vs CD47mAb400). (E) After 8 weeks from initial tumor implantation, the tumors excised from IgG-treated mice were significantly larger than that of anti-CD47 antibody treated mice (ANOVA p < 8e-6, * p < 0.003, ** p < 3e-4). (F) Images of excised subcutaneous tumors are shown.